Metabolic and antihypertensive effects of nebivolol and atenolol in normometabolic patients with mild-to-moderate hypertension

American Journal of Therapeutics

Volumn 6, Issue 3, 1999, Pages 137-147

  Pesant, Yves ^a   Marc Aurèle, Julien ^b   Bielmann, Pierre ^c   Alaupovic, Petar ^d   Cartier, Pierre ^b   Bichet, Daniel ^b   Thibault, Gaetan ^e   Lupien, Paul J ^c  

^a Hôtel Dieu Hospital   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^e CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Lipid lipoprotein metabolism; Normometabolic hypertension; 1 selective blockers

Indexed keywords

ALDOSTERONE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; ATENOLOL; ATRIAL NATRIURETIC FACTOR; C PEPTIDE; CORTICOTROPIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIOTHYRONINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEBIVOLOL; PROLACTIN; THYROTROPIN; THYROXINE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CARBOHYDRATE METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FEMALE; HEART RATE; HUMAN; LIPID METABOLISM; LIPOPROTEIN METABOLISM; MALE; MULTICENTER STUDY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE;

EID: 0032952964     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199905000-00004     Document Type: Article

References (43)

1. Wilhelmsen L, Berglund G, Elmfeldt D, et al: The Multifactor Primary Prevention Trial in Goteborg, Sweden. Eur Heart J 1986;7:279-288.
2. National Cholesterol Education Program: Second Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Bethesda, MD, National Institutes of Health, NIH Publication no. 93-3095, 1993.
3. Laurenzi M, Trevisan M: Sodium-lithium countertransport and blood pressure: the Gubbio Population Study. Hypertension 1989;13:408-415.
4. Laurenzi M, Mancini M, Menotti A, et al: Multiple risk factors in hypertension: results of the Gubbio Study. J Hypertens 1990;8(Suppl):S7-S12.
5. Baba T, Neugebauer J: The link between insulin resistance and hypertension: effects of antihypertensive and antihyperlipidemic drugs on insulin sensitivity. Drugs 1994;47:383-404.
6. Reaven CM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996;334:374-381.
7. Reaven CM: Relationship between insulin resistance and hypertension. Am J Hypertens 1989;2:419-423.
8. Weinberger MH: Antihypertensive therapy and lipids: evidence, mechanisms, and implications. Arch Intern Med 1985;145:1102-1105.
9. Houston MC: New insights and approaches to reduce end-organ damage in the treatment of hypertension: subsets of hypertension approach. Am Heart J 1992;123: 1337-1367.
10. Bielmann P, Leduc G, Germain M, et al: Beta-blockers and changes in lipoprotein fractions. N Engl J Med 1980; 302:298.
11. Klauser R, Prager R, Gaube S, et al: Metabolic effects of isradipine versus hydrochlorothiazide in diabetes mellitus. Hypertension 1991;17:15-21.
12. MacMahon SW, Cutler JA, Furberg CD, et al: The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: review of randomized controlled trials. Prog Cardiovasc Dis 1989;29(Suppl 1):99-118.
13. Pollare T, Lithell H, Berne CA: Comparison of the effects of the hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989;321:868-873.
14. Lithell H: Effect of antihypertensive drugs on insulin, glucose and lipid metabolism. Diabetes Care 1991;14: 203-209.
15. Hedner T, Samuelson O, Lindholm L: Effects of antihypertensive therapy on glucose tolerance: focus on calcium antagonists. J Intern Med 1991;229 (Suppl 2):S101-S112.
16. Berne C, Pollare T, Lithell H: Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE-inhibitors. Diabetes Care 1991;14:39-47.
17. Jauch KW, Hartl W, Guenther B, et al: Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin dependent diabetes mellitus. Eur J Clin Invest 1987;17:448-454.
18. Osaka A, Gajdos M, Fedelesova V, et al: Effects of angiotensin-converting enzyme inhibitors on glucose and lipid metabolism in essential hypertension. J Cardiovasc Pharmacol 1994;23:79-86.
19. Alaupovic P, Mack WJ, Knight-Gibson C, et al: The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 1997;17:715-722.
20. Brunzell JD, Sniderman AD, Albers JJ, et al: Apoproteins B and A-I and coronary artery disease in humans. Arteriosclerosis 1984;4:79-83.
21. Blankenhorn DH, Alaupovic P, Wiekham E, et al: Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and non lipid factors. Circulation 1990;81:470-476.
22. Van der Water A, Janssens W, Van Nueten , et al: Pharmacological and haemodynamic profile of nebivolol, a chemically novel, potent and selective β-adrenergic antagonist. J Cardiovasc Pharmacol 1988;11:552-563.
23. Lacourcière Y, Lefebvre J, Poirier L, et al: Double-blind cross-over comparison of nebivolol and lisinopril in the treatment of ambulatory hypertension. Am J Therapeutics 1994;1:74-80.
24. Moorjani S, Dupont A, Labrie F, et al: Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism 1987;36:244-250.
25. Laurell CB: Electroimmunoassay. Scand J Clin Lab Invest 1972;124(Suppl):21-37.
26. Parra HJ, Mezdur H, Ghalim N, et al: Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates. Clin Chem 1990;36:1431-1435.
27. Fless GM, Snyder ML, Scanu AM: Enzyme-linked immunoassay for Lp(a). J Lipid Res 1989;30:651-662.
28. Armitage P: Statistical Methods in Medical Research, 3rd ed., Oxford: Blackwell Scientific Publications, 1994.
29. Vyssoulis GP, Karapnau EA, Pitssaros CE, et al: Differentiation of beta-blocker effects on serum lipids and apolipoproteins in hypertensive patients with normolipidemic or dyslipidemic profiles. Eur Heart J 1992;13: 1506-1513.
30. Hodis HN, Mack WJ, Labree L, et al: Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized, controlled clinical trial. Ann Intern Med 1996;124:548-556.
31. Lethonen A: Effect of beta-blockers on blcod lipid profile. Am Heart J 1985;109:1192-1196.
32. Maritz FJ, Weich HF, Schoeman HS: A comparison of the metabolic effects of captopril and atenolol on glucose, insulin and lipoproteins in patients with mild-to-moderate essential hypertension. S Afr Med J 1995;85: 1342-1345.
33. Nakoaka H, Amano M, Imataka K, et al: Beta-adrenergic receptor blockade on atrial natriuretic peptide in essential hypertension. Hypertension 1987;10:221-225.
34. Thamsborg G, Sykulski R, Larsen J, et al: Effect of betaladrenoceptor blockade on plasma levels of atrial natriuretic peptide during exercise in normal man. Clin Physiol 1987;7:313-318.
35. Ruskohao H: Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol Rev 1992;44:479-602.
36. Bates ER, Shenker Y, Grekin RJ: The relationship between plasma levels of immunoreactive atrial natriuretic hormone and haemodynamic function in man. Circulation 1986;73:1155-1161.
37. Weidmann P, Ferrari P, Allemann Y, et al: Developing essential hypertension: a syndrome of relative ANF deficiency? Can J Physiol Pharmacol 1991;69:1582-1591.
38. Ortola FV, Ballermann BJ, Anderson S, et al: Elevated plasma atrial natriuretic peptide levels in diabetic rats. J Clin Invest 1987;80:670-674.
39. Deray G, Berlin I, Maistre G, et al: Beta-adrenoceptor blockade potentiates exercise-induced release of atrial natriuretic peptide. Eur J Clin Pharmacol 1990;38:363-366.
40. Fritschka E, Gotzen R, Kittler R, et al: Effect of metoprolol on 24-hr urinary excretion of adrenal steroids and kallikrein in patients with essential hypertension. Br J Pharmacol 1984;81:245-253.
41. Walden RJ, Gotzen R, Kittler R, et al: Withdrawal phenomena after atenolol and bopindolol: hormonal changes in normal volunteers. Br J Clin Pharmacol 1990; 30:547-556.
42. Degli Uberti FC, Portaluppi F, Margutti A, et al: Effect of penbutolol on circadian blood pressure, and renin, aldosterone and cortisol levels in patients with essential hypertension. Acta Cardiol 1988,43:5-20.
43. Mala KL, de Fraites EG, van Kammen DP: Neuroendocrine effects of D, L-propranolol. Lancet 1981;2:424.